The 2013 tuberculosis (TB) review series ‘Tuberculosis: Current state of knowledge’ highlighted important gaps in our existing knowledge on the complex interactions between the pathogen and the host. We also detailed major limitations in current control strategies. Since then, there have been major developments in new diagnostic tools and drugs/regimens for TB and latent TB infection (LTBI), some of which have modified clinical practice in both high‐ and low‐burden countries. In 2014, the World Health Assembly approved the ‘End TB Strategy’, which set ambitious targets to achieve a 95% reduction in TB death and 90% reduction in TB incidence rate by 2035. To consolidate developments and to meet the upcoming challenges, we have invited a panel of international experts to critically re‐examine the relevant issues in a new series of themed reviews focused on TB.Despite over two decades of effort to find and treat infectious sources, there were still an estimated 10.4 million incident TB cases with 1.7 million deaths in 2016. The annual decline of TB incidence remained at around 2%, not much higher than the annual decline of TB mortality of 1.71% in the United Kingdom in the pre‐chemotherapeutic era. Resistance has also emerged to most of
Respirology – Wiley
Published: Jan 1, 2018
Keywords: ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud